Abstract
The Genetics Bundle includes the following reports:
- Bioinformatics Markets.
- DNA Sequencing and PCR Markets.
- Gene Expression Reagents Markets.
- Genomics World Markets.
- Microarray Markets.
- Personalized Medicine.
- Pharmacogenomics for Clinical Use and in Drug Development.
- RNA Interference Markets.
Bioinformatics Markets
The life science informatics marketplace--known as bioinformatics--is set to
expand as high-tech companies infiltrate this arena and biopharmaceutical
companies incorporate key informatic solutions into their business strategies.
TriMark Publications believes that many of the segments of bioinformatics
described in this report offer an unusual opportunity for accelerated
expansion within the coming years. This study is arranged to provide an
overview of bioinformatics market segments and offer evidence that these
segments are poised for significant future growth. Each segment is accompanied
by analysis and forecasts by product type and application. This analysis
surveys the bioinformatics market and the latest information regarding
emerging new products and industry trends. The study will quantify and qualify
the bioinformatics market segments as an area of research, product development
and investment. Forecasts of the bioinformatics market and an analysis of
products in the worldwide information-processing market will provide a basis
for understanding the significance of past developments and future
possibilities within this market category.
DNA Sequencing and PCR Markets
The focus of this TriMark Publications report is to describe the specific
segment of the life sciences market called DNA sequencing. This analysis
includes all of the generally-accepted DNA-oriented analytical activities that
are currently used today, such as enabling technologies like polymerase chain
reaction (PCR). It examines these measurement technology platforms and their
reagents and supplies as utilized in biotechnology research, pharmacology and
healthcare. Generally, diagnostic tests which are marketed primarily as
over-the-counter products directly to patients are not included in this study,
although there is inevitably some overlap. This examination will: 1) identify
viable technology drivers through a comprehensive look at various platform
technologies for molecular sequencing, including immunoassays electrophoretic
methods, probe-based nucleic acid assays, microarrays and non-PCR sequencing;
2) obtain a complete understanding of the chief molecular sequencing tests for
predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic
applications; 3) discover feasible market opportunities via an identification
of high-growth applications in different therapeutic areas, with a focus on
the biggest and expanding markets-communicable diseases, cardiology and
oncology; and 4) focus on global industry development through an in-depth
analysis of the major world markets for molecular sequencing, including
forecasts for growth.
Gene Expression Reagents Markets
The area of gene expression reagents is one of the newest and most important
sectors of pharmaceutical and bioscience research and development. The term
gene expression reagents refers to chemicals that are used in gene expression
experiments that are performed to determine whether a particular gene is
expressed-i.e., present-and in some cases at what levels, in a biological
sample. The purpose of this TriMark Publications report is to describe the
specific segments of the global gene expression reagents market. Within this
area, the study covers those segments that are highly active in terms of
innovation and growth. Specifically, this review examines the markets for gene
expression reagents and small lab equipment all the way up to highly automated
platforms. Emphasis is on those companies that are actively developing and
marketing gene expression reagents for genomics research in the academic
sector and the pharmaceutical, bioscience industry. This study concentrates on
the laboratory reagent market segment and the companion gene expression
reagents sector in the U.S. and around the world that use materials for
genetic research. Particular attention is paid to those areas of the gene
expression reagents sector that are showing the greatest growth or the most
innovation.
Genomics World Markets
Genomics is transforming the pharmaceutical industry. Companies are moving
from drug discovery and development based on medicinal chemistry to the design
of drugs based on information provided by genomics. Virtually all of the major
pharmaceutical houses have either formed partnerships with genomics firms that
began to emerge in the early 1990s or have created in house genomics
divisions. The aim of this TriMark Publications study is to provide in depth
information on the developing market for genomics products and services. The
report will include detailed market analyses and discussions of industry
trends in order to assess the impact of genomics on the current and emerging
pharmaceutical and diagnostic markets. Forecasts and trends were developed
from interviews with industry sources, as well as from an assessment of
available and emerging technologies. The report focuses on how researchers are
applying new genomic approaches to drug discovery and development, and on how
these technologies can be used most effectively and in a high throughput
capacity. Case studies analyzing particular applications of genomic
technologies to specific disease related research are provided, and future
trends and developments are forecasted. Information to prepare this study was
derived from interviews with product managers, marketing strategists, research
executives and others. These individuals are employed at leading genomics
firms or in pharmaceutical and biotechnology companies that either contract
with these firms or have developed in house genomics capabilities.
Microarray Markets
A microarray is an arrangement of miniaturized test sites or "spots" on a
surface. Each spot is usually no more than 250 micrometers in diameter and
contains biological molecules-usually DNA or protein-which act as probes for a
test sample applied to the array. The surface may be a glass slide, a plastic
plate with wells or a polymer bead. The microarray format allows many tests or
experiments to be performed simultaneously, in parallel, leading to the
generation of huge amounts of biological information for the application of
only a tiny amount of sample. Microarrays are often also known as "biochips".
The purpose of this TriMark Publications report is to describe the specific
segment of the microarray market aimed at analysis of proteins and DNA.
Protein microarray applications include: 1) expression profiling; 2)
serum-based diagnostics; 3) protein-protein binding assays; 4 drug-target
binding; and 5) receptor epitope binding. It examines the market for DNA and
protein array testing equipment and supplies using screening reagents and
instruments for analysis of individual components in blood, serum or plasma.
It defines the dollar volume of sales, both worldwide and in the U.S., and
analyzes the factors that influence the size and the growth of the market
segments. Also examined are the subsections of each market segment, including
the research labs, hospital labs, and commercial laboratories. Additionally,
the numbers of institutions using this type of testing and the factors that
influence purchases are discussed. The report surveys almost all of the
companies known to be marketing, manufacturing or developing instruments and
reagents for the protein array market in the U.S. Each company is discussed in
depth with a section on its history, product line, business and marketing
analysis, and a subjective commentary of the company' s market position.
Personalized Medicine
Personalized medicine and pharmacogenomics are inextricably linked.
Pharmacogenomics is the use of genetic variations (such as SNPs, gene
expression variability, or other molecular signatures) to understand and
correlate with differential response to pharmaceutical agents (drugs).
Pharmacogenomics can be deployed clinically to stratify patients into
responders and non-responders and this practice is termed personalized
medicine. The purpose of this TriMark Publications report is to describe the
specific market segment of the diagnostics market called personalized
medicine. To frame the context of current approaches, pharmacogenomics seeks
to identify and validate the signature(s) of molecular analytes and these are
converted to assays using the tools of molecular diagnostics. The deployment
of these molecular diagnostics assays on defining and targeting patient
populations is the domain of personalized medicine. This study includes all of
the generally-accepted imaging activities that are currently used in
personalized medicine, including pharmacogenomics, genomics and theranostics.
It examines associated clinical market segments in which personalized medicine
has taken a prominent role including cancer treatment, cardiology and
neurology markets.
Pharmacogenomics for Clinical Use and in Drug Development
Pharmacogenomics, the science of individualizing drug therapy based on the
genetic makeup of individual patients, offers an unusual opportunity for
future market growth. Applying pharmacogenomics would allow doctors to treat
specific segments of the population based on their particular responses to a
drug. The knowledge of the likely effectiveness of a drug in a patient makes
the drug more reliable, and fewer drugs would have to be taken off the market
due to adverse reactions in some, but not all, of the patients to whom they
were administered. Additionally, reducing the occurrence of adverse effects to
a drug effectually reduces the cost of patient care overall. This TriMark
Publications study examines the market for diagnostic tests based on this
science and the clinical measurement methods, the reagents and supplies being
utilized in clinical medicine and the pharmaceutical industry. This report
presents an overview of the latest information regarding emerging new products
and industry trends and will not only quantify, but also, qualify the
pharmacogenomic market segments as an area of research, product development
and investment opportunity. Forecasts of the pharmacogenomic market and an
analysis of products in the worldwide diagnostics market will provide a basis
for understanding the significance of past developments and the immense
possibilities of the future.
RNA Interference Markets
Since its discovery, the naturally occurring RNA (ribonucleic acid)
interference effect has been acclaimed as the most exciting technical
breakthrough in biological research in the last decade. Some industry analysts
predict that RNA interference (RNAi) may even surpass PCR as a top technology.
RNAi allows scientists to silence the expression or effect of a gene under
study. This is known as gene knockdown. This field has rapidly emerged as a
fast-growing new market. The purpose of this TriMark Publications report is to
review the market for RNAi testing equipment and supplies. RNAi is a mechanism
in molecular biology where the presence of certain fragments of
double-stranded RNA (dsRNA) interferes with the expression of a particular
gene which shares a similar sequence with the dsRNA. This study defines the
dollar volume of sales, both worldwide and in the U.S., and analyzes the
factors that influence market size and growth for RNAi testing. The main
objectives of this study are to: 1) understand the different sectors of RNAi
testing market and to look at a description of the instruments, reagents and
supplies marketed by major companies in each segment; 2) obtain a complete
understanding of the individual RNAi-testing platforms-from basic principles
to clinical applications; 3) discover feasible market opportunities by
identifying high-growth applications in different analytical diagnostic areas,
with a focus on the biggest and expanding markets; 4) focus on global industry
developments and trends through an in-depth analysis of the major world
markets for RNAi measurement technology, including growth forecasts; and 5)
present market figures related to the current value of RNAi testing, market
projections, market share, key players and sector growth rates.
| 
View Cart
